Trial Profile
Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Feb 2024
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary) ; Encorafenib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms EBIN
- 02 Nov 2023 Planned primary completion date changed from 1 Apr 2022 to 1 Nov 2023.
- 02 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 18 Sep 2022 This trial has been completed in Denmark, according to European Clinical Trials Database record.